Melinta Therapeutics to Present at the JMP Securities Life Sciences Conference

NEW HAVEN, Conn. , June 13, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that Dan Wechsler , President and CEO of Melinta, will

READ FULL TEXT

Leave a Reply

Your email address will not be published.